Chatterjee, Sampurna <br/><br/>
Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer.  [electronic resource] 

 -  Cancer research  May 2014 
 - 2816-24 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1538-7445 
<br/><br/><label>Standard No.: </label>10.1158/0008-5472.CAN-13-2986  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--administration & dosage<br/>Animals<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Carcinoma, Non-Small-Cell Lung--blood supply<br/>Cell Line, Tumor<br/>Drug Synergism<br/>Erlotinib Hydrochloride<br/>Humans<br/>Lung Neoplasms--blood supply<br/>Male<br/>Mass Spectrometry<br/>Mice<br/>Mice, Nude<br/>Multimodal Imaging<br/>Phthalazines--administration & dosage<br/>Piperidines--administration & dosage<br/>Positron-Emission Tomography<br/>Protein Kinase Inhibitors--administration & dosage<br/>Pyridines--administration & dosage<br/>Quinazolines--administration & dosage<br/>Receptors, Platelet-Derived Growth Factor--antagonists & inhibitors<br/>Receptors, Vascular Endothelial Growth Factor--antagonists & inhibitors<br/>Xenograft Model Antitumor Assays